Welcome to our dedicated page for Equillium news (Ticker: EQ), a resource for investors and traders seeking the latest updates and insights on Equillium stock.
Equillium Inc. (EQ) is a clinical-stage biotechnology company pioneering therapies for severe autoimmune and inflammatory disorders. This news hub provides investors and stakeholders with timely updates on EQ's scientific advancements, regulatory milestones, and corporate developments.
Access curated press releases and analysis covering key areas including clinical trial results, regulatory communications, research partnerships, and financial performance updates. Our repository simplifies tracking of EQ's novel therapeutic candidates like itolizumab (anti-CD6) and cytokine inhibitors in development.
Bookmark this page for streamlined monitoring of Equillium's progress in addressing conditions such as graft-versus-host disease and lupus nephritis through immunomodulatory approaches. Return regularly for verified updates directly from company filings and authorized sources.
Equillium, Inc. (Nasdaq: EQ) announced a new assay for measuring CD6 engagement as a pharmacodynamic marker in autoimmune diseases at the CYTO Virtual Interactive Meeting. The assay, highlighted by Stephen Connelly, achieves up to 96% receptor occupancy in fresh T cells, aiding in optimizing dosages for itolizumab, a monoclonal antibody targeting CD6. This development supports ongoing clinical trials for conditions including graft-versus-host disease and lupus. The assay was developed in collaboration with Precision for Medicine.
Equillium, a clinical-stage biotechnology company, announced its participation in the JMP Securities Life Sciences Conference on June 16-17, 2021. CEO Bruce Steel will overview itolizumab’s mechanism and ongoing clinical programs, focusing on the EQUATE study data for acute graft-versus-host disease, which will be revealed on June 11, 2021, at EHA. Attendees can access a live webcast of the presentation on the company’s website. Equillium develops itolizumab for severe autoimmune and inflammatory disorders, addressing critical medical needs.
Equillium, Inc. (Nasdaq: EQ) announced a collaboration with the Kennedy Institute for Rheumatology and the University of Oxford to study itolizumab, a CD6 monoclonal antibody, for severe autoimmune disorders. This research will investigate how itolizumab influences T cell responses through the CD6-ALCAM pathway, crucial in rheumatic diseases. With less than 25% of rheumatoid arthritis patients achieving remission on standard treatments, this collaboration aims to develop novel therapeutic strategies. The study is expected to enhance the understanding of CD6 biology and improve treatment outcomes.
Equillium, Inc. (Nasdaq: EQ) will host a conference call on June 11, 2021, at 8:00 am ET to discuss topline data from the EQUATE study of itolizumab for treating acute graft-versus-host disease (aGVHD) at EHA2021 Virtual Congress. The conference will feature speakers like Dolca Thomas, M.D., Steve Connelly, Ph.D., and CEO Bruce Steel, followed by a Q&A session. The company emphasizes that the risk-benefit profile supports advancing itolizumab in first-line therapy for severe autoimmune disorders. A live webcast will be accessible on their website.
Equillium, a clinical-stage biotech company, announced its participation in the Jefferies Virtual Healthcare Conference, scheduled for June 1-4, 2021. CEO Bruce Steel and Dr. Dolca Thomas will discuss ongoing clinical programs for itolizumab, targeting severe autoimmune disorders, including acute graft-versus-host disease, lupus/lupus nephritis, and uncontrolled asthma. The presentation is set for June 2 at 11:00 AM ET, accessible via a live webcast on their website, with an archived replay available for 90 days.
Equillium, Inc. (Nasdaq: EQ) announced the presentation of three posters at the 2021 AAI Annual Meeting, showcasing the novel mechanism of action of itolizumab. This first-in-class monoclonal antibody targets the CD6-ALCAM pathway to modulate T cell responses, which are crucial in autoimmune diseases. Key findings include significant reductions in pro-inflammatory cytokine secretion and the development of a pharmacodynamic biomarker assay to monitor CD6 levels in patients. The research underscores the potential of itolizumab in treating conditions like aGVHD and lupus.
Equillium, Inc. (Nasdaq: EQ) reported positive results from its Phase 1b EQUALISE study in systemic lupus erythematosus, showing safety and a dose-dependent reduction in CD6 expression on T cells. The company raised $29.9 million from a direct offering, boosting its cash reserves to $104.1 million, sufficient to fund operations into late 2023. R&D expenses rose to $5.9 million, increasing the net loss to $9.0 million for Q1 2021, compared to $7.8 million last year. Upcoming data catalysts for 2021 include topline results from the EQUATE study and interim data from the EQUALISE study.
Equillium, Inc. (Nasdaq: EQ) announced positive data from its EQUATE study of itolizumab in acute graft-versus-host disease (aGVHD). An abstract detailing these results has been accepted for oral presentation at EHA2021 on June 11, 2021. The study involves 10 patients with Grade III-IV aGVHD and aims to evaluate safety and efficacy. Itolizumab is designed for first-line treatment of aGVHD, a condition with no approved therapies. The observed benefit-risk profile supports further randomized trials to establish its clinical potential.
Equillium, Inc. (Nasdaq: EQ) announced the presentation of three posters at the 2021 American Association of Immunologists Annual Meeting. These posters focus on itolizumab, a drug targeting the CD6-ALCAM pathway, and its effects on T cell modulation. Key presentations include an assay to monitor CD6 engagement as a biomarker, emphasizing its role in treating autoimmune disorders. The posters will be presented on May 10 and May 14, 2021, showcasing itolizumab’s mechanism and potential clinical applications in conditions like lupus and graft-versus-host disease.
Equillium, Inc. (Nasdaq: EQ) announced positive topline results from its EQUALISE study, evaluating itolizumab for systemic lupus erythematosus (SLE). Administered subcutaneously, itolizumab was found safe and well tolerated, demonstrating a dose-dependent reduction in cell surface CD6 on effector T cells, indicating drug activity. Adverse events were primarily mild to moderate injection site reactions. The study included two groups: Type A for SLE and Type B for lupus nephritis. The complete data set from Type A will be presented at a future conference, with interim Type B data expected later this year.
